Transforming the way cancer is treated
- The human immune system can tell the difference between normal cells in the body and those it sees as “foreign”, which allows it to focus an attack on the foreign cells while leaving the normal cells alone.
- To do this, our immune systems use “checkpoints” – molecules on certain immune cells that need to be activated (or inactivated) to start an immune response.
- Cancer cells can find ways to use these checkpoints to avoid being attacked by the immune system.
- Kairos Pharma is developing small molecules that target these central checkpoints to induce the immune system into attacking cancer cells.
- In addition, Kairos is developing an activated T cell therapy that transforms a patient’s T cells into killer activated T cells against cancerous stem cells.
Transforming the way cancer is treated
- The human immune system can tell the difference between normal cells in the body and those it sees as “foreign”, which allows it to focus an attack on the foreign cells while leaving the normal cells alone.
- To do this, our immune systems use “checkpoints” – molecules on certain immune cells that need to be activated (or inactivated) to start an immune response.
- Cancer cells can find ways to use these checkpoints to avoid being attacked by the immune system.
- Kairos Pharma is developing small molecules that target these central checkpoints to induce the immune system into attacking cancer cells.
- In addition, Kairos is developing an activated T cell therapy that transforms a patient’s T cells into killer activated T cells against cancerous stem cells.
Next-Generation Science to Address Life-Threatening Diseases
KROS-101 Systemic immune modulator
Stage: Pre-IND Studies
Small molecule agonist of GITR developed to address immunosuppressive activity of solid cancers. KROS-101 is designed to deplete regulatory T cells (Tregs) and activate effector T cells and thereby augment the antitumor immune response.
KROS-102 GITR antagonist
Stage: Preclinical Development
A GITR antagonist that increases the inhibitory regulatory T cell (Treg) functions while hampering T effector cell numbers and function. KROS-102 has been shown to decrease T effector cells and increase Treg cells in a dose dependent fashion.
KROS-201 Activated T cell technology
Stage: IND cleared by FDA/ Phase I study in preparation
Autologous T cells are primed with dendritic cells with antigens targeting glioblastoma cancer stem cells. Cytotoxic and helper T cells are generated ex vivo and infused into patients with recurrent glioblastoma.
KROS-301 Tumor targeting small molecule and checkpoint inhibitor
Stage: Preclinical Development
A small molecule inhibitor with two distinct mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway. NF-KB is a key component for cancer growth and drug resistance.
KROS-301 kills tumor cells in RelA/p65 biomarker positive solid tumors.
KROS-401 Tumor microenvironment immune modulator
Stage: Preclinical Development
Cyclic peptide inhibitor of IL4/IL13 cytokine immune receptors for triple negative breast cancer and in addition, it increases anti-tumor response in conjunction with radiation therapy.
ENV-105 Antibody targeting Endoglin for resistance
Stage: Phase I trial for non-small cell lung cancer with Tagrisso enrolling patients
Multi-institutional Phase 2 randomized trial for prostate cancer with Apalutamide enrolling patients
- Androgen target therapy resistance ( prostate cancer Phase 2 Clinical Trial enrolling patients
- EGFR antagonist resistance (lung cancer) Phase 1 Clinical Trial enrolling patients
ENV-205 Antibody targeting mt DNA
Stage: Preclinical Development
Antibody targeting mitochondrial DNA to reverse chemotherapy resistance (prostate, colon, and pancreatic cancer).
Next-Generation Science to Address Life-Threatening Diseases
KROS-101 Systemic immune modulator
Stage: Pre-IND Studies
Small molecule agonist of GITR developed to address immunosuppressive activity of solid cancers. KROS-101 is designed to deplete regulatory T cells (Tregs) and activate effector T cells and thereby augment the antitumor immune response.
KROS-102 GITR antagonist
Stage: Preclinical Development
A GITR antagonist that increases the inhibitory regulatory T cell (Treg) functions while hampering T effector cell numbers and function. KROS-102 has been shown to decrease T effector cells and increase Treg cells in a dose dependent fashion.
KROS-201 Activated T cell technology
Stage: IND cleared by FDA/ Phase I study in preparation
Autologous T cells are primed with dendritic cells with antigens targeting glioblastoma cancer stem cells. Cytotoxic and helper T cells are generated ex vivo and infused into patients with recurrent glioblastoma.
KROS-301 Tumor targeting small molecule and checkpoint inhibitor
Stage: Preclinical Development
A small molecule inhibitor with two distinct mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway. NF-KB is a key component for cancer growth and drug resistance.
KROS-301 kills tumor cells in RelA/p65 biomarker positive solid tumors.
KROS-401 Tumor microenvironment immune modulator
Stage: Preclinical Development
Cyclic peptide inhibitor of IL4/IL13 cytokine immune receptors for triple negative breast cancer and in addition, it increases anti-tumor response in conjunction with radiation therapy.
ENV-105 Antibody targeting Endoglin for resistance
Stage: Phase I trial for non-small cell lung cancer with Tagrisso enrolling patients.
Multi-institutional Phase 2 randomized trial for prostate cancer with Apalutamide enrolling patients
- Androgen target therapy resistance ( prostate cancer Phase 2 Clinical Trial enrolling patients.
- EGFR antagonist resistance (lung cancer) Phase 1 Clinical Trial enrolling patients.
ENV-205 Antibody targeting mt DNA
Stage: Preclinical Development
Antibody targeting mitochondrial DNA to reverse chemotherapy resistance (prostate, colon, and pancreatic cancer).
Strong Intellectual Property Foundation
PCT/US2016/035318
METHODS AND USE OF COMPOUNDS THAT BIND TO RELA OF NF-KB
PCT/US2015/050906
COMPOSITIONS AND METHODS FOR TREATING FIBROSIS
PCT/US2019/045478
COMPOSITIONS AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASES
PCT/US2020/045570
METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY
PCT/US2017/037558
SENSITIZATION OF TUMORS TO THERAPIES THROUGH ENDOGLIN ANTAGONISM
Strong Intellectual Property Foundation
PCT/US2016/035318
METHODS AND USE OF COMPOUNDS THAT BIND TO RELA OF NF-KB
PCT/US2015/050906
COMPOSITIONS AND METHODS FOR TREATING FIBROSIS
PCT/US2019/045478
COMPOSITIONS AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASES
PCT/US2020/045570
METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY
PCT/US2017/037558
SENSITIZATION OF TUMORS TO THERAPIES THROUGH ENDOGLIN ANTAGONISM
MILESTONES
MILESTONES
2013+
- June 2013 - Spun-off from Cedars-Sinai Medical Center as NanoGB13
- June 2014 - Raised $525k from Founders/Pennsylvania Biotechnology Grant
- July 2016 - Name changed to Kairos Pharma and licensed immunotherapy technology from Cedars-Sinai Medical Center
- November 2019 - Merged with AcTcell Biopharma
2021
- July 2021 - Merged with Enviro Therapeutics
- Planned Launch of ENV105 Prostate Cancer Phase II, ENV105 Non- Small Cell Lung Cancer Phase I, KROS-201 Glioblastoma Phase I
- Activated T cells - Pre-IND work completed
2022
- KROS-101 GITR agonist molecule and KROS-102 antagonist GITR molecule Preclinical studies
- IND approved in 2022 to initiate Phase I trial for glioblastoma for KROS 201
- IND approved for Phase II Prostate Cancer Trial and for Phase I Non-Small Cell Lung Cancer for ENV 105
2023
- Phase I and II multi-center trials with ENV105 enrolling
- Preclinical development of KROS 101, 102, 301, 401
- Safety data from Phase II trial and Phase I trial
2024+
- Efficacy data from Phase II trial and Phase I trial
- KROS 201 Phase I trial
- 5-year Horizon for ENV105 FDA Approval with a Maturing Pipeline of Broader Prospective Applications
- Phase I trials for KROS 101, 401
- Pre IND for KROS 102, 301
